Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Capital Expenditures (2016 - 2024)

Historic Capital Expenditures for Fortress Biotech (FBIO) over the last 11 years, with Q3 2024 value amounting to -$1.4 million.

  • Fortress Biotech's Capital Expenditures fell 13960000.0% to -$1.4 million in Q3 2024 from the same period last year, while for Sep 2024 it was $28000.0, marking a year-over-year decrease of 7777.78%. This contributed to the annual value of $63000.0 for FY2023, which is 9767.96% down from last year.
  • As of Q3 2024, Fortress Biotech's Capital Expenditures stood at -$1.4 million, which was down 13960000.0% from $1.4 million recorded in Q2 2024.
  • Fortress Biotech's 5-year Capital Expenditures high stood at $2.0 million for Q4 2021, and its period low was -$1.4 million during Q3 2024.
  • Its 5-year average for Capital Expenditures is $515000.0, with a median of $500500.0 in 2020.
  • Over the last 5 years, Fortress Biotech's Capital Expenditures had its largest YoY gain of 861875.0% in 2024, and its largest YoY loss of 13960000.0% in 2024.
  • Fortress Biotech's Capital Expenditures (Quarter) stood at $698000.0 in 2020, then surged by 180.37% to $2.0 million in 2021, then plummeted by 95.35% to $91000.0 in 2022, then crashed by 69.23% to $28000.0 in 2023, then tumbled by 5082.14% to -$1.4 million in 2024.
  • Its Capital Expenditures stands at -$1.4 million for Q3 2024, versus $1.4 million for Q2 2024 and $28000.0 for Q4 2023.